A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
Completed · Phase 3 · NCT03957590
Conditions: Esophageal Squamous Cell Carcinoma (ESCC)
At a glance
- Research payments reported, 2025
- $9,000
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 370
About the trial
- Sponsor
- BeiGene
- Tested
- Tislelizumab (drug), Placebo (drug), Paclitaxel (drug), Cisplatin (drug), Radiotherapy (radiation)
- Dates
- Started 2019-06-11; completion 2025-03-31
- Results posted
- Yes
This is a phase 3, randomized, double-blind, placebo-controlled study to compare the efficacy and safety of tislelizumab (BGB-A317) versus placebo in combination with chemoradiotherapy in participants with localized esophageal squamous cell carcinoma (ESCC).
From ClinicalTrials.gov, last updated 2026-04-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene, Ltd. reported $9,000 in research payments for this study in 2025 (9 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Raquel O. Alencar, M.D., PH.D. Radiology · Boston, MA
- Mukesh G. Harisinghani, MD Radiology · Boston, MA
- William H. Moore, M.D. Radiology · Setauket, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sbq Radiology, PLLC $4,965
- Mgpo Radiology Associates $3,535
- Scientia Imaging, LLC $500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.